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Structural basis for inhibition of the
Tob-CNOT7 interaction by a fragment
screening approach
Dear Editor,
Theanti-proliferative protein Tob belongs to the Tob/BTG family
(Matsuda et al., 2001) and plays important roles in cell prolif-
eration, embryonic development, cellular differentiation, cancer
suppression, and apoptosis (Matsuda et al., 2001; Iwanaga
et al., 2003; Ito et al., 2005; Jia andMeng, 2007; Mauxion et al.,
2009; Winkler, 2010). The anti-apoptotic and pro-survival
effects of Tobmay provide a tumor escapemechanism against
chemo- and radiation therapies (Suzuki et al., 2012).
The anti-proliferative mechanism of Tob was revealed by its
complex structure complex with CNOT7 (Caf1) (Horiuchi et al.,
2009), and was further shown to be dependent on CNOT7 or
CNOT8but independent of otherCCR4-NOTcomplex subunits
(Doidge et al., 2012). Two conserved regions of Tob, termed
Box A and Box B, mediate the largely hydrophobic interaction
with CNOT7 and are conserved in other family members,
including BTG2 (Yang et al., 2008). Several reports have sug-
gested that Tob has no appreciable effect on the deadenylase
activityofCNOT7 (Horiuchi et al., 2009;Ezzeddineet al., 2012),
although the precise mechanism by which Tob regulates
CNOT7 deadenylase activity remains unclear.
Protein-protein interactions play a crucial role in most
biological processes and present attractive opportunities for
therapeutic intervention (Pfaff et al., 2015). We employed a
fragment screening approach to discover inhibitors of the
Tob-CNOT7 interaction. Fragment screening is an alterna-
tive method to conventional high-throughput screening using
small compounds of ∼250 Da, which have many more
desirable properties for the discovery of lead compounds
than ∼350 Da compounds used in conventional screening
libraries. The low chemical complexity of fragments enables
a small fragment library to cover more chemical space and
yield a higher hit rate than conventional high-throughput
screening libraries (Hann et al., 2001).
To identify chemical compounds that speciﬁcally bind to
Tob, we screened 2000 fragments from The Drug Discovery
Initiative (DDI) library that are soluble at 200 μmol/L in a
buffer containing 5% DMSO. Tob stability was conﬁrmed in a
buffer containing 5% DMSO (Fig. S2). Initial screening was
performed by surface plasmon resonance (SPR) on the CM5
sensor chip. The SPR response reﬂects the change of mass
on chip surface directly, and is sensitive enough to detect
binding of fragments to proteins on the chip (Giannetti et al.,
2008). We selected speciﬁc binders based on the shape of
the sensorgrams (Fig. 1A): sensorgrams with slow dissoci-
ation (signals are kept for 10 s after buffer injection) were
treated as non-speciﬁc binding, while those with sample
responses higher than 100 response units (RU) were treated
as non-stoichiometric binding (Fig. 1B and 1C). After the
removal of those binders, ∼112 compounds exhibiting the top
5% response in each plate were selected as binding frag-
ments to Tob (Fig. 1D and 1E).
A second round of competitive screening was conducted
to identify inhibitors of the interaction between Tob and
CNOT7. Because the responses of the fragments were
much smaller than the response of CNOT7 in SPR, the
mixture of the inhibitor and CNOT7 shows a smaller
response than CNOT7 alone. Each compound selected from
the library of 2,000 compounds was mixed with CNOT7 and
injected. Addition of some fragments resulted in a decrease
of RU, suggesting that they inhibited the Tob-CNOT7 inter-
action (Fig. 1F). After the second round of screening, 20
compounds with an inhibition rate higher than 20% were
selected as inhibitors of the interaction between Tob and
CNOT7 (Fig. 1G). The structure of the hit compounds and
their rates of inhibition are shown in Table S1.
To provide structural insight into fragment binding, crys-
tals of human Tob residues 1–138 (termed TobN138 here-
after), containing Box A and B motifs, were soaked with a
buffer containing several fragments. Structures of TobN138
with two inhibitors, corresponding to compounds 1 (i1) and 6
(i6) (Table S1), were determined to 2.3 Å resolution
(Table S2). TobN138 consists of ﬁve α-helices and four β-
strands that form two anti-parallel β-sheets. The highly
conserved Box A region includes β1, α3, α2 and the con-
necting loop between them. The Box B region consists of the
anti-parallel strands β2 and β3. The inhibitor-bound struc-
tures reveal two distinct binding sites in the CNOT7-binding
interface of Tob (Fig. 2A and 2B).
In the TobN138-i1 complex, i1 π-stacks against Trp93 and
is coordinated by the side-chain of Ser53. Superimposing
© The Author(s) 2015. This article is published with open access at Springerlink.com and journal.hep.com.cn










the Tob-i1 complex onto the Tob-CNOT7 complex structure
shows that i1 overlaps with Ser201 and Cys202 on helix α10
of CNOT7 (Fig. 2C). Trp93 is highly conserved among the
Tob/BTG family and is located in the Box B motif (Fig. S1).
Asp95 and Glu98 of Tob form a salt bridge with Lys203 in
CNOT7, while Trp93 inserts into a hydrophobic pocket on
the CNOT7 surface. A CNOT7 K203A mutant abrogates the
interaction with Tob (Horiuchi et al., 2009), while BTG2
W103A and D105A mutants were unable to interact with
CNOT7 (Yang et al., 2008). Trp103 and Asp105 of BTG2 are
strictly conserved with residues Trp93 and Asp95 of Tob.
The i6 complex structure revealed two inhibitor molecules
from the electron density map. The ﬁrst is located in the
CNOT7 interface close to Box A, where i6 is coordinated by
Lys63 and Asp89 and stacks loosely against His59 (Figs. 2A
and S3B). In the Tob-CNOT7 complex structure, Lys63 forms
a number of contacts to the CNOT7 residues Tyr197 and
Lys254, whereas residues His59 and Asp89 of Tob do not
interact with CNOT7. Superposition of Tob-i6 and Tob-
CNOT7 structures shows that i6 largely overlaps with Tyr197
in CNOT7. Lys63 of Tob adopts an extended side chain
conformation in the inhibitor-bound structure and would
clash with Lys254 in CNOT7 (Fig. 2D). His59 and Lys63 are
located on the periphery of the Box A motif, with His59
located on strand β1 and Lys63 in the β1-α4 loop. Neither
residue is strictly conserved in the Tob/BTG family (Fig. S1).
Lack of sequence conservation in this site together with the
low inhibition by i6 suggests it is dispensable for the CNOT7
interaction, but could be useful for design of inhibitors tar-
geting speciﬁc Tob/BTG family members. The second inhi-
bitor stacks against the aromatic side chain of Phe97,
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Figure 1. Discovery of Tob-CNOT7 inhibitors by fragment screening. (A–C) The binding analysis of compounds to Tob using
Biacore shows three different responses. (A) Compounds showing responses of fast association and fast dissociation are treated as
speciﬁc binding. (B) Compounds with responses of slow association and slow dissociation are treated as non-speciﬁc binding. The
arrows indicate sample and buffer injection points as indicated. (C) Compounds showing responses higher than 100 RU are treated
as non-stoichiometric binding. (D and E) Two representative results in the ﬁrst round of screening for compounds that bind speciﬁcally
to Tob. We tested one plate containing 384 compounds per day using SPR. Each green square corresponds to one compound and
each red square corresponds to running buffer as a negative control. Non-stoichiometric bindings are not included. Compounds
exhibiting the top 5% response in each plate were selected as binding fragments to Tob. (F and G) The screening for compounds that
inhibit the Tob-CNOT7 interaction identiﬁed 20 compounds. (F) Competitive inhibition, as shown by a decrease in the response unit
when the compound competes with CNOT7 for binding to Tob. (G) Compounds with % inhibition higher than 20% (red line) are
selected as hits.
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stabilized by a hydrogen bond between the O9 atom and the
side chain of Glu47, in the Box A motif. Glu47 and Phe97 are
strictly conserved in the Tob/BTG family, but this binding site
is distant from the CNOT7 interface.
To test the importance of these two binding sites for inter-
action with CNOT7, two inhibitor binding residues (Lys63 in
Box A, Trp93 in Box B) were individually mutated and the
resulting mutant proteins were assayed for their ability to bind
to CNOT7. Both the wild-type protein and K63A mutant were
able to interact with CNOT7 in vitro (Fig. 2E and 2F), with
respective dissociation constants (Kd) of 3.25 × 10
7 M−1 ±
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measured by isothermal calorimetry (ITC) (Fig. S4 and
Table S3). Due to poor expression and stability of the Tob
W93A mutant, we were unable to test the interaction of this
mutant with CNOT7 in vitro, although themutant expressed in
mammalian cells for subsequent interaction assays in vivo.
The equivalent BTG2W103Amutant was also unstable, but a
G64A-W103A doublemutant could be expressed (Yang et al.,
2008). However, expression of the equivalent Tob G54A-
W93A double mutant also proved unsuccessful in this study.
In vivo co-immunoprecipitation experiments of CNOT7 with
wild-type Tob and the K63A and W93A conﬁrmed that wild-
type Tob and the K63A mutant, but not the W93A mutant,
could interact with Flag-CNOT7 (Fig. 2G).
The effects of Tob or inhibitor binding on mRNA dead-
enylation mediated by CNOT7 were examined by in vitro
deadenylase assays with single-strand poly(A) RNA.
A D95A mutant was constructed as a negative control to
substitute for W93A. The conserved Asp95 in Box B of Tob is
equivalent to Asp105 of BTG2, which abrogates the inter-
action with CNOT7 (Yang et al., 2008). GST pull-down
conﬁrmed that Tob D95A was unable to interact with CNOT7
(Fig. 2E and 2F). When increasing amounts of wild-type and
mutant Tob proteins were individually added to the CNOT7
deadenylase reaction system, the activity of CNOT7 in the
presence of wild-type Tob and the K63A mutant was sup-
pressed (Fig. 2H). No apparent differences were observed
between CNOT7 alone and CNOT7 in the presence of the
Tob D95A mutant (Fig. 2H).
Our study used a fragment-screening approach to
identify a series of compounds that inhibit the Tob-CNOT7
interaction. Structural analysis of two fragment inhibitors
delineated two distinct binding sites on Tob. The ﬁrst
shows 96.4% inhibition and binds to a strictly conserved
site located on Box B in the CNOT7 interface, including
residues Trp93 and Asp95. Missense mutations W93A and
D95A abolish the interaction between Tob and CNOT7
in vitro and in vivo. The second inhibitor shows 43%
inhibition and binds to a site close to Box A in the CNOT7
interface; mutation of Lys63 in this site reduces the binding
afﬁnity between Tob and CNOT7 to 47% of the wild-type.
Our results indicate that Box B of Tob should be targeted
for efﬁcient inhibition of the Tob-CNOT7 interaction. Such
inhibitors might prove useful as functional tools to probe
the detailed biological role of Tob-CNOT7, or to speciﬁcally
block the anti-apoptotic activity of Tob as a new avenue for
development of anti-cancer therapeutics (Suzuki et al.,
2012).
We further showed that Tob, but not the Tob D95A mis-
sense mutant, suppresses the deadenylase activity of
CNOT7 in vitro. BTG2 also suppresses the activity of
CNOT7 in vitro, while no appreciable effect on CNOT7
deadenylase activity was reported when a 4 molar excess of
TobN138 was added (Yang et al., 2008; Horiuchi et al.,
2009). In contrast, Tob1, Tob2, and BTG2 promote dead-
enylation and mRNA degradation in cellular transfection
assays (Ezzeddine et al., 2007; Mauxion et al., 2009; Doidge
et al., 2012; Ezzeddine et al., 2012). The underlying mech-
anism for this is unclear, but promotion by Tob of deadeny-
lation and mRNA degradation in vivo may be linked to its
interaction with PABP via its C-terminal PAM2 motifs
(Ezzeddine et al., 2007), and Tob alone suppresses dead-
enylation and mRNA degradation. Further work is underway
to test this hypothesis.
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Coordinates and structure factors for the Tob-i1 complex have been
deposited in the Protein Data Bank with accession number 5CI8.
Coordinates and structure factors for the Tob-i6 complex have been
deposited in the Protein Data Bank with accession number 5CI9.
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Figure 2. Structural analysis of Tob inhibitors. (A) Overall
structure of Tob in complex with inhibitors 1 and 6. Tob is shown
in pale green cartoon representation with the Box A and Box B
motifs coloured red and blue, respectively. Inhibitors located in
the CNOT7-binding interface of Tob are highlighted. The
structure of the Tob-CNOT7 complex (PDB ID: 2D5R) is
superimposed for comparison, with CNOT7 shown in pale blue
cartoon representation. (B) Surface view of Tob shows the
location of i1 and i6. The colour scheme is consistent with panel
(A). (C) View of the i1 binding site showing the inhibitor
overlapping with helix a10 of CNOT7. (D) View of the i6 binding
site, showing the inhibitor overlapping with Tyr197C of CNOT7
and Lys63 of Tob clashing with Lys254C of CNOT7. (E and F)
GST pull-downs using recombinant GST tagged CNOT7 and
TobN138 (wild type, K63A, D95A mutants). GST served as a
negative control. The migration of a molecular weight size
marker is indicated. (G) Interaction of CAF1 with Tob wild-type
and the mutants in vivo. Cos7 cells were transfected with Tob
expression vector (WT, K63A, or W93A mutant) together with
control or Flag-CNOT7 expression vector. Lysates were pre-
pared from the cells and immunoprecipitated with anti-Flag
antibody. The lysates and immunoprecipitates (IP) were ana-
lyzed by immunoblot using the indicated antibodies. (H) Dead-
enylase assay of CNOT7 with wild-type TobN138, K63A and
D95A mutants in vitro. CNOT7 alone or CNOT7 with TobN138
wild-type, K63A and W95A mutant proteins were incubated with
5′-ﬂuorescein isothiocyanate-labeled RNA substrate (RNA 3′-
7 N + 20 As) for 30 min.
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